Navigation Links
City of Baltimore to Evaluate New Generation Biofuels for Use in Boiler Applications
Date:5/7/2009

LAKE MARY, Fla., May 7 /PRNewswire-FirstCall/ -- Renewable fuels provider New Generation Biofuels Holdings, Inc. (Nasdaq: NGBF) today announced that it has signed a contract with the City of Baltimore, Maryland,("the City") to provide its renewable biofuel in an evaluation program for boiler applications in the heart of Baltimore. This is the first time the City of Baltimore has evaluated a non fossil fuel in its industrial boilers.

In this program, New Generation Biofuels will sell the City biofuel for evaluation in various city municipal buildings. The outcome of the evaluation is expected to further validate New Generation Biofuels' product as a renewable biofuel which uniquely offers NOx and SO2 reductions as compared to traditional distillate products and provide a platform for the City of Baltimore to expand its RFP definitions to include alternative technology biofuels such as New Generation Biofuels in future tender submissions.

"We are enthusiastic to be working with the City of Baltimore on this evaluation program," said New Generation Biofuels' Chief Executive Officer, Cary Claiborne. "The City of Baltimore understands the importance of a sustainable biofuel to reduce overall greenhouse gas emissions and the importance of using a clean, efficient fuel." Mr. Claiborne continued, "In addition, our biofuel can be used as a 100 percent fuel switch with minimal modification to a customer's equipment."

Department of Public Works (DPW) Energy Advisor Ted Atwood stated, "The Energy Office is constantly looking for new and innovative ways to reduce and save on energy costs in sustainable ways that will benefit our City now and into the future. To that end, I am eager to start the evaluation phase."

About New Generation Biofuels Holdings, Inc.

New Gen
'/>"/>

SOURCE New Generation Biofuels Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Three Firms, Two Training Programs Garner Greater Baltimore Committees 2009 Bioscience Awards
2. Greater Baltimore Committee to Announce Winners of 2009 Maryland Bioscience Awards at Ceremonies on March 12
3. New Generation Biofuels Completes Construction of Baltimore Facility
4. Baltimore LASIK Surgeon Roy Chuck, MD, PhD of the Wilmer Eye Institute at Johns Hopkins Lists with Trusted LASIK Surgeons
5. Blake M. Paterson MD, CEO and Co-founder of Alba Therapeutics, Wins Greater Baltimore Committee 2008 Leadership in Bioscience Award
6. Three CEOs and University President Named Winners of Greater Baltimore Committees 2008 Baltimore Region Bioscience Awards
7. Greater Baltimore Committee to Announce Winners of Third Baltimore Region Bioscience Awards at Ceremonies on March 18
8. University of Maryland, Baltimore BioPark Signs Gliknik Inc. as First Tenant in Its BioInnovation Center in Building Two
9. Cerimon Pharmaceuticals Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain
10. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
11. MicroDose and Nexus6 Announce Collaboration to Evaluate Application of Remote Patient Compliance Monitoring Technology with MicroDoses Electronic Dry Powder Inhaler
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2EUCODIS Bioscience Appoints Thomas Fischer as New CEO 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3